
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
HIVers concerned about the potential development of drug resistance might want to talk with their physicians about taking a boosted protease inhibitor-based cocktail rather than one containing a nonnucleoside analog, according to a report in the journal Clinical Infectious Diseases. An analysis of nearly 8,000 HIVers showed that those who experienced virologic failure while on a nonnuke regimen were significantly more likely to develop resistance to nucleoside analogs--including to multiple drugs in that medication class--than were HIVers on failing PI regimens. More than half of the HIVers on a failing nonnuke regimen also developed resistance to all three medications in their cocktails, compared to just 0.9% of those experiencing viral rebound on a PI-based regimen.
From our Sponsors
Most Popular
Plus: Featured Video